# Biolink Life Sciences, Inc.

Canonical: https://abierto.us/vendors/biolink-life-sciences-inc-gusqrgkrz4c9

- UEI: GUSQRGKRZ4C9
- CAGE: 1WR74
- Location: Cary, NC
- Awards in window: 1 (2 transactions), -$542,764 obligated, May 14, 2024 to July 16, 2025

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 1 awards, -$542,764

## Industries

- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): -$542,764

## Competition

- Competed Under SAP: 1 awards

## Largest awards

- 75A50122C00068 (definitive contract): -$542,764, Barda - Aspr / Daappo / Barda DCMA. Biolink - to Investigate and Determine If Treatment with Ramatroban, Administered for 28 Days to Hospitalized, NON-ICU Patients with Covid-19 Pneumonia, Reduces the Risk of Subsequent Development of Pasc Over the Ensuing 11 Months. Provided Data. https://www.usaspending.gov/award/CONT_AWD_75A50122C00068_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/biolink-life-sciences-inc-gusqrgkrz4c9.